Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Unternehmen & Branche
| Name | Zentalis Pharmaceuticals, Inc. |
|---|---|
| Ticker | ZNTL |
| CIK | 0001725160 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 290,5 Mio. USD |
| Beta | 1,66 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 0 | -137,060,000 | -1.91 | 288,967,000 | 216,204,000 |
| 2025-09-30 | 10-Q | 0 | -26,691,000 | -0.37 | 327,250,000 | 252,874,000 |
| 2025-06-30 | 10-Q | 0 | -26,874,000 | -0.37 | 351,707,000 | 274,495,000 |
| 2025-03-31 | 10-Q | 0 | -48,279,000 | -0.67 | 384,021,000 | 295,382,000 |
| 2024-12-31 | 10-K | 67,425,000 | -165,839,000 | -2.33 | 430,337,000 | 337,186,000 |
| 2024-09-30 | 10-Q | 0 | -40,158,000 | -0.56 | 450,661,000 | 354,331,000 |
| 2024-06-30 | 10-Q | 0 | -88,277,000 | -1.24 | 491,680,000 | 382,581,000 |
| 2024-03-31 | 10-Q | 40,560,000 | 10,068,000 | 0.14 | 557,479,000 | 458,771,000 |
| 2023-12-31 | 10-K | 0 | -292,191,000 | -4.47 | 551,688,000 | 437,284,000 |
| 2023-09-30 | 10-Q | 0 | -55,528,000 | -0.79 | 585,715,000 | 481,768,000 |
| 2023-06-30 | 10-Q | 0 | -112,527,000 | -1.85 | 621,444,000 | 523,141,000 |
| 2023-03-31 | 10-Q | 0 | -63,219,000 | -1.07 | 489,342,000 | 385,487,000 |
| 2022-12-31 | 10-K | 0 | -236,806,000 | -4.48 | 539,310,000 | 433,803,000 |
| 2022-09-30 | 10-Q | -54,401,000 | -0.96 | 529,193,000 | 428,504,000 | |
| 2022-06-30 | 10-Q | -68,357,000 | -1.34 | 567,856,000 | 472,490,000 | |
| 2022-03-31 | 10-Q | -59,077,000 | -1.31 | 405,677,000 | 315,298,000 | |
| 2021-12-31 | 10-K | -50,059,000 | -1.11 | 454,507,000 | ||
| 2021-09-30 | 10-K | -4,191,000 | -0.09 | |||
| 2021-09-30 | 10-Q | -4,191,000 | -0.09 | 435,081,000 | 393,432,000 | |
| 2021-06-30 | 10-K | -54,574,000 | -1.34 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-10 | Vultaggio Vincent | Officer, PAO and PFO | Open Market Sale | -6,894 | 2.42 | -16,699.34 | -101,8% | |
| 2026-02-09 | Bruns Ingmar | Officer, Chief Medical Officer | Open Market Sale | -335 | 2.39 | -801.62 | -4,9% | |
| 2026-02-09 | Vultaggio Vincent | Officer, PAO and PFO | Open Market Sale | -3,379 | 2.39 | -8,085.61 | -49,3% | |
| 2026-02-09 | EASTLAND JULIA MARIE | Director, Officer, CEO & President | Open Market Sale | -889 | 2.39 | -2,127.29 | -13,0% | |
| 2026-02-06 | Vultaggio Vincent | Officer, PAO and PFO | Open Market Sale | -29,951 | 2.43 | -72,771.94 | -443,6% | |
| 2026-02-06 | Bruns Ingmar | Officer, Chief Medical Officer | Open Market Sale | -2,962 | 2.43 | -7,196.77 | -43,9% | |
| 2026-02-06 | EASTLAND JULIA MARIE | Director, Officer, CEO & President | Open Market Sale | -7,866 | 2.43 | -19,112.02 | -116,5% | |
| 2026-02-03 | Vultaggio Vincent | Officer, PAO and PFO | Open Market Sale | -556 | 2.52 | -1,398.34 | -8,5% | |
| 2026-02-02 | Vultaggio Vincent | Officer, PAO and PFO | Open Market Sale | -2,540 | 2.55 | -6,477.00 | -39,5% | |
| 2025-04-30 | Myers Scott Dunseth | Director | Open Market Purchase | 21,000 | 1.40 | 29,372.70 | +179,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.